A clinical study comparing SGLT-2 inhibitor tofogliflozin vs pioglitazone showed that hepatic steatosis significantly decreased in both groups after 24 weeks of treatment, but to a greater extent with pioglitazone than with tofogliflozin. Here, SLC5A2 is linked to fatty liver disease.